SynthesisMolecular biology reports2026
Natural products targeting the molecular pathology of salivary gland mucoepidermoid carcinoma: A systematic review of In vitro studies.
Synthesis in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMucoepidermoid carcinoma of the salivary glands has limited systemic treatment options, while natural products have the potential to inhibit tumor survival by modulating multiple molecular pathways. This study aims to elucidate the antitumor activity, biological mechanisms, and translational potential of natural products in a preclinical model of mucoepidermoid carcinoma.
methodA systematic review was conducted in accordance with PRISMA and registered with PROSPERO (CRD420261404862). PubMed, Scopus, ProQuest, ScienceDirect, and Taylor & Francis were searched through July 2026 for studies evaluating the effects of natural products on human mucoepidermoid carcinoma cell lines. Eligibility was based on evidence from human MEC cell-line models in vitro; studies with a corresponding in vivo xenograft component were also eligible, with in vivo findings extracted as supportive translational validation. Data on viability, apoptosis, cell cycle, and molecular pathways were synthesized narratively and mechanistically, while xenograft findings were summarized separately where available. Methodological quality was assessed using QUIN and SciRAP.
resultsFourteen in vitro studies met the inclusion criteria, including four that involved xenograft validation. Overall, the interventions impaired viability or proliferation within a cytotoxic range and primarily induced apoptosis, as evidenced by changes in nuclear morphology, increased Annexin V/PI and sub-G1 fractions, mitochondrial membrane depolarization, caspase activation, and PARP cleavage. A cross-study synthesis revealed mechanistic convergence on ERK/MAPK, Mcl-1, XIAP, and STAT3, linking disruption of survival signaling to mitochondrial apoptosis and the caspase execution phase. Mcl-1 was the most frequently identified anti-apoptotic regulator, while autophagy assessed in two studies demonstrated a cytoprotective function. Heterogeneity in compounds, concentrations, cell lines, and measurement methods hinders comparisons of potency among candidates.
conclusionNatural products exhibit antiproliferative and proapoptotic activity in a mucoepidermoid carcinoma model by targeting several converging survival pathways. These findings support their development as a source of lead compounds.
Indexed as
Identifiers
42726157What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.